Blog

Careers

Advertise

Contact

logo
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • Events
    • National Pharmacy Forum 2021
    • Past Events
  • CHeS
    • CHeS Total Visibility Project
    • CHeS Membership
    • CHeS Resources
  • Issues
  • Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • Small Supplier Portal
    • Congressional Resources
    • COVID-19 Recommendations
  • News
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • Events
    • National Pharmacy Forum 2021
    • Past Events
  • CHeS
    • CHeS Total Visibility Project
    • CHeS Membership
    • CHeS Resources
  • Issues
  • Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • Small Supplier Portal
    • Congressional Resources
    • COVID-19 Recommendations
  • News

Comments of the Healthcare Supply Chain Association (HSCA) to FDA on Facilitating Competition and Innovation in the Biological Products Marketplace

September 21, 2018 by admin 2018 Press Releases 0 comments

On behalf of the Healthcare Supply Chain Association (HSCA), thank you for the opportunity to provide comments on the U.S. Food and Drug Administration’s (FDA) “Facilitating Competition and Innovation in the Biological Products Marketplace.”

The ability to safely substitute FDA-approved biosimilars for reference biologics will be critical to realizing the full cost-savings potential of biosimilars and will ensure that patients have timely access to safe, less-costly therapies. HSCA and its member healthcare group purchasing organizations are committed to lowering costs through increased competition and innovation in the healthcare marketplace and have consistently advocated for policies to ensure a pathway to market for biosimilars that prioritizes patient safety and cost savings.

We applaud the FDA for recognizing the value of a competitive and innovative biosimilars marketplace and respectfully offer the following recommendations to promote the swift uptake of biosimilar products:

Read the full comments…

Prev
Next

Related Posts

Comments of the Healthcare Supply Chain Association on the Department of Health and Human Services Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
July 16, 2018

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...

Learn more
HSCA Statement on Senate HELP Committee Hearing on Reducing Costs through Innovation
November 28, 2018

Washington, DC (November 28, 2018) – Healthcare Supply Chain Association (HSCA)...

Learn more
Comments of the Healthcare Supply Chain Association (HSCA) to FDA on Facilitating Competition and Innovation in the Biological Products Marketplace
September 21, 2018

On behalf of the Healthcare Supply Chain Association (HSCA), thank you for the...

Learn more
Comments of the Healthcare Supply Chain Association (HSCA) on Supported Lifetimes and Legacy Medical Devices
May 31, 2018

Advances in information technology and medical devices, and increasing...

Learn more

Our Office

Healthcare Supply Chain Association
1341 G Street NW Suite 600
Washington, DC 20005

Phone: 202.629.5833
Fax: 202.466.9666
Email: info@supplychainassociation.org

LATEST NEWS

  • HSCA Submits Comments to FDA on Using Unique Device Identifiers in Medical Device Safety Communications to Support Accuracy, Quality, and Patient Safety
    January 18, 2021
  • HSCA Comments to the U.S. ITC on COVID-19 Related Goods: The U.S. Industry, Market, Trade, and Supply Chain Challenges
    October 5, 2020